A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults
Latest Information Update: 25 Sep 2024
Price :
$35 *
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- Acronyms ZOSTER-049; ZOSTER-049 EXT:006-022
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 07 Feb 2024 Status changed from active, no longer recruiting to completed.
- 22 Sep 2023 This trial has been completed in Czechia (Date of the global end of the trial: 28-Jun-2023), according to the European Clinical Trials Database record.
- 02 May 2023 The trial has been completed in Germany, according to European Clinical Trials Database record.